JP2007520209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520209A5 JP2007520209A5 JP2006541900A JP2006541900A JP2007520209A5 JP 2007520209 A5 JP2007520209 A5 JP 2007520209A5 JP 2006541900 A JP2006541900 A JP 2006541900A JP 2006541900 A JP2006541900 A JP 2006541900A JP 2007520209 A5 JP2007520209 A5 JP 2007520209A5
- Authority
- JP
- Japan
- Prior art keywords
- rejection
- colorant
- bases
- chronic
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003086 colorant Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009788 parenchymal fibrosis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52672203P | 2003-12-03 | 2003-12-03 | |
| PCT/EP2004/013727 WO2005054503A2 (en) | 2003-12-03 | 2004-12-02 | Biomarkers for graft rejection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097258A Division JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007520209A JP2007520209A (ja) | 2007-07-26 |
| JP2007520209A5 true JP2007520209A5 (https=) | 2008-01-24 |
| JP4316617B2 JP4316617B2 (ja) | 2009-08-19 |
Family
ID=34652465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541900A Expired - Fee Related JP4316617B2 (ja) | 2003-12-03 | 2004-12-02 | 移植片拒絶反応のバイオマーカー |
| JP2009097258A Pending JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097258A Pending JP2009195234A (ja) | 2003-12-03 | 2009-04-13 | 移植片拒絶反応のバイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20070111210A1 (https=) |
| EP (1) | EP1694860A2 (https=) |
| JP (2) | JP4316617B2 (https=) |
| WO (1) | WO2005054503A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070086A2 (en) | 2004-01-21 | 2005-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| USRE46843E1 (en) | 2005-03-14 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
| EP2604703B1 (en) | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
| GB0605217D0 (en) * | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
| GB0606776D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
| GB0607943D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Biomarkers for chronic transplant dysfunction |
| CA2650507A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2049713A4 (en) * | 2006-07-21 | 2010-06-16 | Univ Alberta | tissue rejection |
| EP2066809A2 (en) * | 2006-08-28 | 2009-06-10 | Source Precision Medicine | Gene expression profiling for identification, monitoring and treatment of transplant rejection |
| JP2008151517A (ja) * | 2006-12-14 | 2008-07-03 | Niigata Univ | 腎障害の判定方法 |
| EP2031073A1 (en) * | 2007-08-31 | 2009-03-04 | TC LAND Expression | Diagnostic of immune graft tolerance using TMTC3 gene expression levels |
| EP2279270B1 (en) * | 2008-04-15 | 2014-06-18 | Oberbauer, Rainer | Markers of acute kidney failure |
| WO2010021696A1 (en) * | 2008-08-18 | 2010-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| ES2492498T3 (es) | 2009-01-15 | 2014-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto |
| US20120165207A1 (en) * | 2009-02-12 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for Monitoring Allograft Rejection |
| EP2507630B1 (en) | 2009-12-02 | 2017-01-25 | The Board of Trustees of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| WO2011119980A1 (en) | 2010-03-25 | 2011-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Protein and gene biomarkers for rejection of organ transplants |
| WO2012052994A2 (en) * | 2010-10-17 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Markers of primary graft dysfunction |
| US8962261B2 (en) | 2011-04-06 | 2015-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Autoantibody biomarkers for IGA nephropathy |
| WO2012156513A1 (en) * | 2011-05-18 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for determining whether a subject is at risk of having or developing a chronic kidney disease |
| EP2834638B1 (en) * | 2012-04-02 | 2020-02-12 | Astute Medical, Inc. | Methods for diagnosis and prognosis of sepsis |
| EP2671574A1 (en) * | 2012-06-04 | 2013-12-11 | VitaK B.V. | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
| PL2875049T3 (pl) * | 2012-07-18 | 2019-07-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd) |
| US10961580B2 (en) | 2014-12-19 | 2021-03-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting graft alterations |
| US20200174014A1 (en) | 2016-12-19 | 2020-06-04 | Osaka University | METHOD FOR IN VITRO EARLY DIAGNOSIS OF ANTIBODY MEDIATED REJECTION AFTER ORGAN TRANSPLANTATION USING IgM-TYPE MEMORY B CELL DIFFERENTIATION CULTURE SYSTEM |
| CN110960672B (zh) * | 2019-12-18 | 2020-10-16 | 西南民族大学 | 一种提高牦牛免疫能力的aif-1蛋白注射液 |
| WO2025199256A1 (en) * | 2024-03-20 | 2025-09-25 | Alkahest, Inc. | Longitudinal sample sets and methods of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527884A (en) * | 1993-12-21 | 1996-06-18 | President And Fellows Of Harvard College | Mediators of chronic allograft rejection and DNA molecules encoding them |
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US20030104371A1 (en) * | 1997-09-24 | 2003-06-05 | Strom Terry B. | Methods of evaluating transplant rejection |
| US6187534B1 (en) * | 1997-09-24 | 2001-02-13 | Cornell Research Foundation, Inc. | Methods of evaluating transplant rejection |
| US20030113744A1 (en) * | 2001-05-11 | 2003-06-19 | O' Toole Margot M. | Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| GB0200929D0 (en) * | 2002-01-16 | 2002-03-06 | Univ Glasgow | Tissue rejection |
| US20060099591A1 (en) * | 2002-08-22 | 2006-05-11 | Andreas Krause | Diagnosis of chronic rejection |
-
2004
- 2004-12-02 WO PCT/EP2004/013727 patent/WO2005054503A2/en not_active Ceased
- 2004-12-02 JP JP2006541900A patent/JP4316617B2/ja not_active Expired - Fee Related
- 2004-12-02 EP EP04801199A patent/EP1694860A2/en not_active Withdrawn
- 2004-12-02 US US10/581,068 patent/US20070111210A1/en not_active Abandoned
-
2009
- 2009-04-13 JP JP2009097258A patent/JP2009195234A/ja active Pending
- 2009-07-13 US US12/501,706 patent/US20090269334A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,839 patent/US20120039868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520209A5 (https=) | ||
| Tan et al. | MicroRNA-24-3p attenuates myocardial ischemia/reperfusion injury by suppressing RIPK1 expression in mice | |
| Theis et al. | Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome | |
| McBride et al. | Linkage analysis of left ventricular outflow tract malformations (aortic valve stenosis, coarctation of the aorta, and hypoplastic left heart syndrome) | |
| Donate‐Correa et al. | Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease | |
| Larsen et al. | Histopathologic findings associated with APOL1 risk variants in chronic kidney disease | |
| Neumann et al. | MicroRNA 628-5p as a novel biomarker for cardiac allograft vasculopathy | |
| SG186940A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| EP2904118B1 (en) | Urine exosome mrnas and methods of using same to detect diabetic nephropathy | |
| JP2013519095A5 (https=) | ||
| JP2012517592A5 (https=) | ||
| Nakashima et al. | Lifelong clinical impact of the presence of sarcomere gene mutation in Japanese patients with hypertrophic cardiomyopathy | |
| McLeod et al. | Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations | |
| Tran et al. | Association between AGT M235T and left ventricular mass in Vietnamese patients diagnosed with essential hypertension | |
| Kiewisz et al. | WNT4 expression in primary and secondary kidney diseases: dependence on staging | |
| Algharably et al. | Uromodulin associates with cardiorenal function in patients with hypertension and cardiovascular disease | |
| US20060003338A1 (en) | System and methods for the management and treatment of vascular graft disease | |
| ES2380929T3 (es) | Diagnóstico de rechazo crónico | |
| Song et al. | Integrated strategies of diverse feature selection methods identify aging-based reliable gene signatures for ischemic cardiomyopathy | |
| Muniz et al. | Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms | |
| Abd El-Fattah et al. | Association of genetic variants of hemostatic genes with myocardial infarction in Egyptian patients | |
| CN105132565A (zh) | 用于心脏病诊断和分型的超敏分子标志物及其应用 | |
| Hohenadel et al. | Gene expression in diabetic nephropathy | |
| Badr et al. | Association of genetic variants of pentraxin 3 rs3816527 with hypertension in Chronic kidney disease patients | |
| CN108004316A (zh) | 用于预测急性心肌梗死风险的试剂盒 |